Gyn Path Services, INC.

Gyn Path Services, INC. was paid $6.92M by Medicaid between Jan 2018 and Dec 2024, across 27 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 13% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#23 of 436

Median peer was paid$17K

This provider vs. median401×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,682	$156K
2019	4,738	$142K
2020	17,852	$739K
2021	61,149	$2.11M
2022	57,301	$1.91M
2023	38,820	$1.06M
2024incomplete	29,387	$801K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	13%	12,639	10,920	$926K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	13%	12,951	10,943	$895K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	12%	29,990	28,833	$805K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	12%	29,958	28,801	$805K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	8.5%	22,218	21,269	$586K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	8.1%	27,441	26,615	$563K
81513		8.0%	6,676	6,315	$556K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	7.0%	21,201	17,962	$482K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	5.6%	14,233	13,850	$385K
87653		3.2%	8,514	8,091	$224K
87481		2.9%	7,595	7,149	$198K
88305	Level IV - Surgical pathology, gross and microscopic examination	1.7%	1,265	1,227	$117K

15 more codes

88141		1.5%	5,980	$106K
88377		<1%	200	$57K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	931	$51K
87081		<1%	8,537	$42K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	794	$34K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,682	$34K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	192	$25K
87625		<1%	462	$12K
87563		<1%	252	$6K
87800		<1%	129	$5K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	35	$677.50
87480		<1%	14	$268.02
87510		<1%	14	$267.84
87660		<1%	14	$247.08
0831T		0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMILES, PHILIP (MEDICAL DIRECTOR)